Multiple sclerosis: A current overview of failed and interrupted treatment trials;Multiple sklerose. Aktuelle ubersicht zu fehlgeschlagenen und abgebrochenen therapiestudien

Nervenarzt

Volumn 71, Issue 8, 2000, Pages 597-610

  Wiendl, H ^a   Neuhaus, O ^a   Kappos, L ^b   Hohlfeld, R ^a,c  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Altered peptide ligands; APL; Cladribine; Deoxyspergualine; Extracorporeal photopheresis; IL 10; IVIg; Linomide; Multiple sclerosis; Oral tolerance; Sulfasalazine; TGF 2; TNF antagonist

Indexed keywords

15 DEOXYSPERGUALIN; AI 100; CLADRIBINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 10; LENERCEPT; MYELIN BASIC PROTEIN; MYLORAL; ROQUINIMEX; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERANCE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PUVA; REMYELINIZATION; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOANTIGENS; CLINICAL TRIALS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; PHOTOPHERESIS; TREATMENT FAILURE;

EID: 0033897315     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050636     Document Type: Review

References (86)

1. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives
2. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force
3. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis
4. Tumor necrosis factor: Developments during the last decade
5. The tumor necrosis factor ligand and receptor families
6. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
7. The adhesion molecule and cytokine profile of multiple sclerosis lesions
8. TNF-alpha receptor fusion protein prevents experimental auto-immune encephaolmyelitis and demyelination in Lewis rats: An overview
9. Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system
10. Increased production of interferon gamma and tumor necrosis factor preceds clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations?
11. Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis
12. Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis
13. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity
14. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients
15. Tumor-necrosis-factor-alpha messenger-RNA Expression in patients with relapsing-remitting multiple-sclerosis is associated with disease-activity
16. Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis
17. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
18. TNF neutralization in MS
19. Treatment of rheumatoid arthritis with chimeric monoclonal antibody to tumor necrosis factor alpha
20. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
21. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
22. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1
23. Regulation of antibody production and class switching by TFG-β
24. Transforming growth factors β1 and β2: Cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T cell function
25. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1
26. Protective effect of transforming growth factor-β1 on experimental autoimmune diseases in mice
27. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease
28. Transforming growth factor-β1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis
29. TGF-β2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo
30. Phase-1 trial of transforming-growth-factor-beta-2 in chronic progressive MS
31. Transforming growth factor β: The good, the bad, and the ugly
32. Interleukin-10 induces a long term antigen-specific anergic state in human CD4+ T-cells
33. Interleukin-10 prevents experimental allergic encephalomyelitis in rats
34. Staphylococcus enterotoxin B and tumor-necrosis factor-alpha induced relapses of experimental allergic encephalomyelitis: Protection by transforming growth factor-β and interleukin-10
35. Il-10 fails to abrogate experimental autoimmune encephalomyelitis
36. Interferon effects on interleukin-10 secretion: Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients
37. Low serum interleukin-10 levels in multiple sclerosis: Further evidence for decreased systemic immunosuppression?
38. A randomized controlled trial of Il-10 in humans: Inhibition of inflammatory cytokine production and immune responses
39. Linomide, a novel immunomodulator that prevents death in four models of septic shock
40. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator Linomide
41. Treatment of chronic relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide)
42. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
43. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
44. Linomide in relapsing and secondary progressive MS. Part I: Trial design and clinical results
45. Linomide in relapsing and secondary progressive MS. Part II: MRI results
46. Lessons from Linomide: A failed trial but not a failure
47. Sulfasalazine: Pharmacology, clinical use, toxicity, and related new drug development
48. Pharmacological and biochemical actions of sulfasalazine
49. Suppression of experimental autoimmune encephalitis by sulfasalazine
50. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine
51. The mayo-clinic canadian cooperative trial of sulfasalazine in active multiple sclerosis
52. Multiple sclerosis trials
53. European multicenter trial ± deoxyspergualine (DSG) versus placebo: Results of the first interim analysis
54. Deoxyspergualine in the treatment of active MS: Final analysis of the European multicenter Study
55. Cladribine (2-chlorodeoxyadenosine)
56. Cladribine in treatment of chronic progressive multiple sclerosis
57. The treatment of chronic progressive multiple sclerosis with cladribine
58. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
59. Intravenous immunoglobulin treatment of neurological autoimmune disorders
60. Immunoglobulins promote remyelination in the central nervous system
61. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis
62. Immunoglobulin administration does not reverse visual-acuity loss in long-standing optic neuritis associated with multiple sclerosis
63. Intravenous immunoglobulin does not reverse recently acquired, apparently permanent weakness in multiple sclerosis
64. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
65. Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes
66. Oral tolerance: Immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens
67. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
68. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
69. MRI results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
70. Clinical results of a phase III trial of oral myelin in relapsing-remitting multiple sclerosis
71. Immuno-modulation of experimental autoimmune encephalomyelitis by oral administration of copolymer-I
72. Antigen-based immunotherapy for autoimmune disease: From animal models to humans?
73. Altered peptide ligand induced partial T cell activation: Molecular mechanisms and role in T cell biology
74. Modulation of cytokine patters of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand
75. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
76. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis
77. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
78. Disease modifying treatments for multiple sclerosis: What is on the horizon?
79. Antigen-specific immunomodulation confirms the encephalitogenic potential of Myelin basic protein peptide (83-99) in Multiple Sclerosis
80. Induction of a non-encephalitogenic Th2 autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo controlled, radomized phase II trial
81. Treatment of cutaneous T cell lymphoma by extracorporeal photochemistry: Preliminary results
82. Treatment of psoriatic arthritits with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation
83. Extracorporeal photochemotherapy in progressive systemic sclerosis: A follow-up study
84. Anti-idiotype network induced by T cell vaccination against experimental autoimmune encephalomyelitis
85. Specific vaccination against photoinactivated cloned T cells
86. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis